Press release
Frontotemporal Dementia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
"Frontotemporal Dementia Pipeline Insight, 2025 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.
The Frontotemporal Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Frontotemporal Dementia Pipeline Report: https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Frontotemporal Dementia treatment therapies with a considerable amount of success over the years.
• Frontotemporal Dementia companies working in the treatment market are Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others, are developing therapies for the Frontotemporal Dementia treatment
• Emerging Frontotemporal Dementia therapies in the different phases of clinical trials are- Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others are expected to have a significant impact on the Frontotemporal Dementia market in the coming years.
• In May 2025, Vesper Bio ApS announced that it has achieved a key enrollment milestone in the Phase Ib/IIa portion of its ongoing SORT-IN-2 trial for its lead candidate, VES001. This study focuses on asymptomatic individuals carrying a mutation in the progranulin (GRN) gene, which is linked to a major genetically driven form of frontotemporal dementia (FTD), known as FTD-GRN.
• In January 2025, Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company dedicated to treating neurodegenerative diseases, has provided updated findings from its ongoing Phase 1/2 upliFT-D trial evaluating PBFT02 for frontotemporal dementia (FTD) with granulin (GRN) mutations. Additionally, the company highlighted key upcoming milestones and announced the successful completion of process development and scale-up for a suspension-based manufacturing process of PBFT02. As the program progresses, Passage Bio has reassessed its operational requirements and will shift to an outsourced analytical testing model.
• In November 2024, CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company dedicated to developing therapies for age-related neurological conditions, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its oral investigational treatment, neflamapimod, for frontotemporal dementia (FTD).
• In September 2024, Vesper Bio shared findings from a Phase I trial evaluating VES001, a potential disease-modifying therapy for frontotemporal dementia (FTD), specifically in patients with progranulin gene (GRN) mutations. The first participant was dosed in December last year. The study, involving 78 healthy volunteers, aimed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic target engagement of VES001.
• In April 2024, AviadoBio has announced that the initial patient has received treatment in the Phase I/II ASPIRE-FTD trial, which is assessing the company's experimental gene therapy, AVB-101, for individuals with frontotemporal dementia (FTD) caused by progranulin (GRN) gene mutations (FTD-GRN).
• In February 2024, Transposon Therapeutics has released interim findings from its Phase II trial of TPN-101, focusing on patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) associated with hexanucleotide repeat expansions in the C9orf72 gene (C9orf72-related ALS/FTD).
• In February 2024, Alector, Inc. and GSK plc have reported that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to latozinemab for its potential use in treating frontotemporal dementia associated with a progranulin gene mutation (FTD-GRN).
Frontotemporal Dementia Overview
Frontotemporal dementia (FTD) is a collective term for a set of disorders caused by gradual loss of function in the brain's frontal and temporal lobes. These brain regions are crucial for behavior, language, and decision-making skills.
Get a Free Sample PDF Report to know more about Frontotemporal Dementia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Frontotemporal Dementia Drugs Under Different Phases of Clinical Development Include:
• Research programme CNS Therapies: Deep Genomics
• Research Program M1 PAM: Asceneuron SA
• AVB-101: AviadoBio
• Research programme CNS: CAMP4 Therapeutics
• NI308: Neurimmune
• PR006: Prevail Therapeutics
• PBFT02: Passage Bio
• TPN-101: Transposon Therapeutics
• AL001: Alector Inc.
Frontotemporal Dementia Route of Administration
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Frontotemporal Dementia Molecule Type
Frontotemporal Dementia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Frontotemporal Dementia Pipeline Therapeutics Assessment
• Frontotemporal Dementia Assessment by Product Type
• Frontotemporal Dementia By Stage and Product Type
• Frontotemporal Dementia Assessment by Route of Administration
• Frontotemporal Dementia By Stage and Route of Administration
• Frontotemporal Dementia Assessment by Molecule Type
• Frontotemporal Dementia by Stage and Molecule Type
DelveInsight's Frontotemporal Dementia Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Frontotemporal Dementia product details are provided in the report. Download the Frontotemporal Dementia pipeline report to learn more about the emerging Frontotemporal Dementia therapies
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Frontotemporal Dementia Therapeutics Market include:
Key companies developing therapies for Frontotemporal Dementia are - Alector Inc., Transposon Therapeutics, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio, Inc., Prevail Therapeutics, Wave Life Sciences, and others.
Frontotemporal Dementia Pipeline Analysis:
The Frontotemporal Dementia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia Treatment.
• Frontotemporal Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Frontotemporal Dementia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Frontotemporal Dementia drugs and therapies
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Frontotemporal Dementia Pipeline Market Drivers
• Increasing prevalence of geriatric population, increasing drug development grants, increasing collaborations among companies are some of the important factors that are fueling the Frontotemporal Dementia Market.
Frontotemporal Dementia Pipeline Market Barriers
• However, lack of proper diagnosis, higher chances of misunderstanding with Alzheimer's disease and other factors are creating obstacles in the Frontotemporal Dementia Market growth.
Scope of Frontotemporal Dementia Pipeline Drug Insight
• Coverage: Global
• Key Frontotemporal Dementia Companies: Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others
• Key Frontotemporal Dementia Therapies: Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others
• Frontotemporal Dementia Therapeutic Assessment: Frontotemporal Dementia current marketed and Frontotemporal Dementia emerging therapies
• Frontotemporal Dementia Market Dynamics: Frontotemporal Dementia market drivers and Frontotemporal Dementia market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frontotemporal Dementia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight here
News-ID: 4148580 • Views: …
More Releases from DelveInsight Business Research
Global Injectable Drug Delivery Devices Market to grow at a CAGR of 11.26% by 20 …
According to DelveInsight's analysis, The growth in demand for injectable drug delivery devices is largely driven by the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders, the increasing adoption of self-injectors, expansion of the biologics and biosimilars market, the growing emphasis on patient compliance with treatments, and continuous innovations and technological advancements in the field.
DelveInsight's "Injectable Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2030" report…
Abdominal Aortic Aneurysm Market Expected to Gain Momentum Through 2034, Accordi …
DelveInsight's "Abdominal Aortic Aneurysm Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Abdominal Aortic Aneurysm, historical and forecasted epidemiology as well as the Abdominal Aortic Aneurysm market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Abdominal Aortic Aneurysm market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Abdominal Aortic Aneurysm…
Focal Segmental Glomerulosclerosis Market to Witness Promising Upswing by 2034, …
DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market…
Heart Failure Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and K …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Heart Failure pipeline constitutes 70+ key companies continuously working towards developing 75+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Heart Failure Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
The Heart…
More Releases for Frontotemporal
Frontotemporal Dementia Market Set to Double by 2034, Reaching USD 4.2 Billion
The global FTD market was valued at USD 2.1 billion in 2024 and is projected to reach USD 4.2 billion by 2034, growing at a CAGR of 7.1%. Rising diagnosis rates, growing investment in neurodegenerative disease research, and expanded healthcare access are driving this growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70788
Key Market Highlights
• Increasing recognition of FTD as distinct from Alzheimer's and other dementias.
• Expanding pipeline of clinical trials…
Frontotemporal Disorders Treatment Market Projected Touch Approximately USD 7.68 …
Forecast Increase in Revenue:
Frontotemporal Disorders Treatment Market is expected to reach USD 7.68 Bn at a CAGR of 7.3% during the forecast period 2030.
Frontotemporal Disorders Treatment Market Overview:
The Frontotemporal Disorders Treatment Market focuses on the management and treatment of neurological conditions that cause damage to the brain's frontal and temporal lobes, leading to disorders such as dementia, progressive supranuclear palsy, and primary progressive aphasia. These conditions significantly impact behavior, language,…
Frontotemporal Dementia Treatment Market - Empathy in Action: Pioneering Frontot …
Newark, New Castle, USA: The "Frontotemporal Dementia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Frontotemporal Dementia Treatment Market: https://www.growthplusreports.com/report/frontotemporal-dementia-treatment-market/8569
This latest report researches the industry structure,…
Frontotemporal Dementia Treatment Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "Frontotemporal Dementia Treatment Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly studies…
Frontotemporal Disorder Treatment Market Size, Share, Impressive Industry Growth …
The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number…
Improvement In Cognitive Empathy to Drive The Frontotemporal Dementia Treatment …
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
